Bank of America is a multinational financial services company that provides a wide range of banking and financial solutions to individuals, businesses, and institutional clients. The company offers services such as consumer banking, commercial banking, investment banking, asset management, and wealth management. With a robust network of branches and digital platforms, Bank of America aims to deliver accessible and innovative financial products, including mortgages, credit cards, and investment advisory services. The organization is committed to supporting economic growth and sustainability while serving a diverse clientele across various markets. Read More
GE HealthCare Technologies (NASDAQ:GEHC) executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge.
Speaking at a Bank of
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic m
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
Jonathan Lim, Erasca’s chair
Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification
Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference.
Speaking
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.
Speaking at a Bank of America fireside chat host
Akamai stock is soaring as Bank of America says the company is rapidly emerging as a major AI infrastructure player, boosting its price target to $175.
ADDISON, Texas, May 15, 2026 (SEND2PRESS NEWSWIRE) -- Click n' Close, a multi-state mortgage lender, announced strategic engagement of Christy Soukhamneut and Launch Point Advisory Group to support the expansion of its Whole Loan Trading division. The move is part of a broader initiative to grow Click n' Close's secondary market presence and offer whole loan trading opportunities across its government and specialty loan programs.
CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.
Speak
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less roo...
Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
Ryan Kohlhepp of
What Happened? Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 3.7% in the afternoon session after a Reuters report indicated the US...
What Happened? A number of stocks jumped in the afternoon session after optimism improved supported by the U.S.-China trade summit and solid U.S. economic da...
Chime Financial delivered its first profitable quarter as revenue growth, margin expansion, and loan growth strengthened the fintech’s future prospects.
